Last reviewed · How we verify
TAK-085
At a glance
| Generic name | TAK-085 |
|---|---|
| Sponsor | Takeda |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation (PHASE4)
- Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood (PHASE4)
- Efficacy of TAK-085 in Participants With Hypertriglyceridemia (PHASE3)
- Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |